NASDAQ:ANAB - AnaptysBio Stock Price, Price Target & More

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio (NASDAQ:ANAB) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.19. During the same quarter in the prior year, the business earned ($0.75) earnings per share. View AnaptysBio's Earnings History.

8 brokerages have issued 1 year price targets for AnaptysBio's stock. Their forecasts range from $40.00 to $180.00. On average, they expect AnaptysBio's stock price to reach $138.6250 in the next year. View Analyst Ratings for AnaptysBio.

AnaptysBio saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 2,515,518 shares, an increase of 43.4% from the March 30th total of 1,754,800 shares. Based on an average trading volume of 578,333 shares, the days-to-cover ratio is presently 4.3 days. Currently, 15.1% of the company's stock are sold short.

Some companies that are related to AnaptysBio include SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), FibroGen (FGEN), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH) and Ligand Pharmaceuticals (LGND).

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

News articles about ANAB stock have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AnaptysBio earned a media sentiment score of 0.18 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 44.78 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

AnaptysBio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FRAZIER HEALTHCARE V, LP (15.70%), FRAZIER HEALTHCARE V, LP (15.70%), FRAZIER HEALTHCARE V, LP (9.93%), BlackRock Inc. (5.96%), OppenheimerFunds Inc. (4.46%) and Redmile Group LLC (2.23%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.

ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Franklin Resources Inc., VHCP Management II LLC, Citigroup Inc., BNP Paribas Arbitrage SA, JPMorgan Chase & Co., Spark Investment Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold AnaptysBio company stock in the last year include Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Insider Buying and Selling for AnaptysBio.

ANAB stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Millennium Management LLC, Artal Group S.A., Royal Bank of Canada, UBS Group AG, BlackRock Inc., Senzar Asset Management LLC and Guggenheim Capital LLC. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ANAB stock can currently be purchased for approximately $77.90.

AnaptysBio has a market capitalization of $1.93 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]